Cue Biopharma (CUE)
Cue Biopharma on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
793K
Short interest
settlement 2026-10-15
3.7
Days to cover
+2.7 days vs prior
63.0%
Short share of volume
2026-11-02
10,410
Fails to deliver
settlement 2026-10-14
Wed 11 Nov
Next earnings
estimated date
-$2.4M
Insider flow, 90 days
0 buys, 15 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CUE is 792,553 shares, up 460,448 shares over the last month. Over the last 48 readings it ranged from 255,157 shares (15 May 2026) to 7,541,901 shares (15 April 2026). The latest reading sits at the bottom of that range. At the reported average volume of 214K shares a day that is 3.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cue" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 792,553 | +12.9% | 213,851 | 3.71 |
| 2026-09-30 | 702,198 | +111.4% | 666,076 | 1.05 |
| 2026-09-15 | 332,105 | +4.3% | 136,259 | 2.44 |
| 2026-08-31 | 318,420 | -2.8% | 180,671 | 1.76 |
| 2026-08-14 | 327,442 | -6.4% | 200,890 | 1.63 |
| 2026-07-31 | 349,876 | +13.6% | 184,644 | 1.89 |
| 2026-07-15 | 307,891 | +3.3% | 138,660 | 2.22 |
| 2026-06-30 | 298,077 | +8.4% | 111,200 | 2.68 |
| 2026-06-15 | 274,983 | -1.0% | 73,707 | 3.73 |
| 2026-05-29 | 277,694 | +8.8% | 107,168 | 2.59 |
| 2026-05-15 | 255,157 | -11.7% | 2,034,085 | 1.00 |
| 2026-04-30 | 288,887 | -96.2% | 533,660 | 1.00 |
| 2026-04-15 | 7,541,901 | +183.1% | 44,894,553 | 1.00 |
| 2026-03-31 | 2,664,499 | +17.2% | 3,385,101 | 1.00 |
| 2026-03-13 | 2,272,639 | +27.6% | 1,059,938 | 2.14 |
| 2026-02-27 | 1,781,535 | -10.0% | 293,366 | 6.07 |
| 2026-02-13 | 1,978,661 | -8.6% | 438,687 | 4.51 |
| 2026-01-30 | 2,165,317 | +16.8% | 2,055,161 | 1.05 |
| 2026-01-15 | 1,853,300 | +28.6% | 1,823,121 | 1.02 |
| 2025-12-31 | 1,440,523 | +290.6% | 2,165,183 | 1.00 |
| 2025-12-15 | 368,757 | -16.5% | 311,764 | 1.18 |
| 2025-11-28 | 441,825 | -13.3% | 181,939 | 2.43 |
| 2025-11-14 | 509,612 | +39.6% | 569,375 | 1.00 |
| 2025-10-31 | 365,072 | +6.1% | 186,331 | 1.96 |
| 2025-10-15 | 344,086 | -44.6% | 361,781 | 1.00 |
| 2025-09-30 | 620,911 | -6.8% | 173,490 | 3.58 |
| 2025-09-15 | 665,931 | -25.9% | 129,012 | 5.16 |
| 2025-08-29 | 898,157 | -6.1% | 126,769 | 7.08 |
| 2025-08-15 | 956,793 | +10.8% | 121,882 | 7.85 |
| 2025-07-31 | 863,107 | -22.4% | 751,168 | 1.15 |
| 2025-07-15 | 1,112,261 | -4.2% | 226,010 | 4.92 |
| 2025-06-30 | 1,161,283 | +39.6% | 419,466 | 2.77 |
| 2025-06-13 | 831,592 | +7.4% | 134,984 | 6.16 |
| 2025-05-30 | 774,133 | -13.3% | 202,045 | 3.83 |
| 2025-05-15 | 892,678 | +3.0% | 117,797 | 7.58 |
| 2025-04-30 | 867,049 | -1.9% | 137,371 | 6.31 |
| 2025-04-15 | 883,413 | +3.7% | 295,310 | 2.99 |
| 2025-03-31 | 851,924 | -0.9% | 90,887 | 9.37 |
| 2025-03-14 | 859,887 | -10.0% | 217,597 | 3.95 |
| 2025-02-28 | 955,190 | -6.5% | 138,521 | 6.90 |
| 2025-02-14 | 1,021,829 | -6.9% | 177,741 | 5.75 |
| 2025-01-31 | 1,097,311 | +1.4% | 331,212 | 3.31 |
| 2025-01-15 | 1,081,952 | -17.0% | 498,995 | 2.17 |
| 2024-12-31 | 1,303,485 | +21.2% | 325,525 | 4.00 |
| 2024-12-13 | 1,075,268 | +7.0% | 311,113 | 3.46 |
| 2024-11-29 | 1,004,624 | -5.9% | 490,773 | 2.05 |
| 2024-11-15 | 1,067,781 | -40.0% | 765,794 | 1.39 |
| 2024-10-31 | 1,780,964 | -8.6% | 1,000,977 | 1.78 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CUE volume is 63.0%, down 14.2 points over the last five sessions. Over the last 30 readings it ranged from 38.8% (28 October 2026) to 77.2% (26 October 2026). The latest reading is in line with the 30-session average of 62.4%, on 64K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 40K | 64K | 63.0% | 0 |
| 2026-10-30 | 14K | 24K | 60.4% | 0 |
| 2026-10-29 | 14K | 32K | 43.7% | 0 |
| 2026-10-28 | 20K | 53K | 38.8% | 0 |
| 2026-10-27 | 30K | 42K | 73.0% | 0 |
| 2026-10-26 | 43K | 55K | 77.2% | 0 |
| 2026-10-23 | 15K | 28K | 54.3% | 0 |
| 2026-10-22 | 14K | 19K | 73.8% | 0 |
| 2026-10-21 | 37K | 54K | 67.9% | 0 |
| 2026-10-20 | 41K | 73K | 55.3% | 0 |
| 2026-10-19 | 29K | 49K | 59.5% | 2,679 |
| 2026-10-16 | 24K | 40K | 58.8% | 110 |
| 2026-10-15 | 67K | 89K | 75.2% | 0 |
| 2026-10-14 | 68K | 105K | 64.8% | 10,899 |
| 2026-10-13 | 82K | 119K | 69.3% | 12,691 |
| 2026-10-12 | 48K | 91K | 52.6% | 1,092 |
| 2026-10-09 | 130K | 215K | 60.2% | 109 |
| 2026-10-08 | 31K | 50K | 61.2% | 0 |
| 2026-10-07 | 40K | 59K | 68.3% | 400 |
| 2026-10-06 | 50K | 73K | 68.4% | 3,301 |
| 2026-10-05 | 92K | 127K | 72.6% | 11,642 |
| 2026-10-02 | 54K | 74K | 72.9% | 250 |
| 2026-10-01 | 61K | 87K | 70.1% | 0 |
| 2026-09-30 | 40K | 81K | 49.7% | 3,702 |
| 2026-09-29 | 87K | 120K | 72.8% | 6,803 |
| 2026-09-28 | 51K | 109K | 46.6% | 268 |
| 2026-09-25 | 64K | 109K | 59.2% | 35 |
| 2026-09-24 | 95K | 146K | 65.3% | 150 |
| 2026-09-23 | 163K | 346K | 47.0% | 825 |
| 2026-09-22 | 383K | 552K | 69.5% | 22,877 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in CUE is 10,410 shares, up 5,757 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (30 July 2026) to 107,024 shares (23 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 10,410 | $19.57 | $204K |
| 2026-10-08 | 4,653 | $22.51 | $105K |
| 2026-10-02 | 930 | $25.25 | $23K |
| 2026-09-28 | 210 | $31.41 | $7K |
| 2026-09-25 | 16,197 | $32.85 | $532K |
| 2026-09-24 | 2,229 | $31.71 | $71K |
| 2026-09-23 | 107,024 | $30.90 | $3.3M |
| 2026-09-22 | 72,935 | $28.27 | $2.1M |
| 2026-09-18 | 2,924 | $37.84 | $111K |
| 2026-09-17 | 206 | $34.17 | $7K |
| 2026-09-15 | 459 | $30.55 | $14K |
| 2026-09-11 | 180 | $28.00 | $5K |
| 2026-09-10 | 3,801 | $30.50 | $116K |
| 2026-09-09 | 288 | $30.00 | $9K |
| 2026-09-02 | 2,005 | $28.44 | $57K |
| 2026-09-01 | 3,794 | $25.52 | $97K |
| 2026-08-31 | 592 | $27.88 | $17K |
| 2026-08-28 | 22,738 | $28.16 | $640K |
| 2026-08-27 | 2,162 | $28.85 | $62K |
| 2026-08-14 | 549 | $31.08 | $17K |
| 2026-08-13 | 31 | $30.42 | $943 |
| 2026-08-10 | 1,792 | $27.12 | $49K |
| 2026-08-06 | 561 | $26.65 | $15K |
| 2026-08-05 | 4,002 | $26.60 | $106K |
| 2026-08-04 | 2,303 | $26.87 | $62K |
| 2026-08-03 | 2,382 | $26.84 | $64K |
| 2026-07-31 | 32,305 | $30.40 | $982K |
| 2026-07-30 | 4 | $28.01 | $112 |
| 2026-07-28 | 2,979 | $32.57 | $97K |
| 2026-07-27 | 8,724 | $32.12 | $280K |
Insider trades
SEC Form 4, newest first. JSONInsiders at CUE reported 15 open-market sells worth $2.4M in the last 90 days and no open-market buys. Latest filing: Lin Shao-Lee (Chief Executive Officer) on 2026-10-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Lin Shao-Lee | Chief Executive Officer | Sell | 1K | $28.05 | $30K | 695K |
| 2026-10-12 | Lin Shao-Lee | Chief Executive Officer | Sell | 10K | $27.50 | $275K | 696K |
| 2026-10-12 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 1K | $28.05 | $32K | 48K |
| 2026-10-12 | Ray Sumita | Chief Legal Compliance Officer | Sell | 2K | $28.05 | $52K | 117K |
| 2026-08-13 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 3 | $31.13 | $93 | 49K |
| 2026-08-13 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 4K | $30.35 | $125K | 49K |
| 2026-08-13 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 2K | $29.37 | $45K | 53K |
| 2026-08-13 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Exercise or conversion | 14K | $0.00 | $0 | 55K |
| 2026-08-13 | Ray Sumita | Chief Legal Compliance Officer | Sell | 4 | $31.13 | $125 | 119K |
| 2026-08-13 | Ray Sumita | Chief Legal Compliance Officer | Sell | 6K | $30.35 | $196K | 119K |
| 2026-08-13 | Ray Sumita | Chief Legal Compliance Officer | Sell | 2K | $29.37 | $70K | 125K |
| 2026-08-13 | Ray Sumita | Chief Legal Compliance Officer | Exercise or conversion | 18K | $0.00 | $0 | 127K |
| 2026-08-13 | Lin Shao-Lee | Chief Executive Officer | Sell | 10K | $29.48 | $308K | 706K |
| 2026-08-13 | Lin Shao-Lee | Chief Executive Officer | Sell | 2K | $28.11 | $67K | 716K |
| 2026-08-13 | Lin Shao-Lee | Chief Executive Officer | Sell | 5K | $27.19 | $147K | 719K |
| 2026-08-12 | Lin Shao-Lee | Chief Executive Officer | Sell | 6K | $27.75 | $160K | 724K |
| 2026-08-12 | Lin Shao-Lee | Chief Executive Officer | Sell | 34K | $26.99 | $924K | 730K |
| 2026-08-12 | Lin Shao-Lee | Chief Executive Officer | Exercise or conversion | 109K | $0.00 | $0 | 764K |
| 2026-07-30 | Ahlers James M | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 26K |
| 2026-07-13 | Borie Dominique Christian | Chief Medical Officer | Grant | 32K | $0.00 | $0 | 32K |
| 2026-07-09 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | Grant | 41K | $0.00 | $0 | 41K |
| 2026-07-09 | Meehan Viola Mong | Director | Grant | 22K | $0.00 | $0 | 22K |
| 2026-07-09 | Sarraf Pasha | Director | Grant | 22K | $0.00 | $0 | 33K |
| 2026-07-09 | Garzone Pamela | Director | Grant | 22K | $0.00 | $0 | 22K |
| 2026-07-09 | Lin Shao-Lee | Chief Executive Officer | Grant | 328K | $0.00 | $0 | 655K |
| 2026-07-09 | Ray Sumita | Chief Legal Compliance Officer | Grant | 55K | $0.00 | $0 | 109K |
| 2026-07-09 | Camardo Daniel A. | Director | Grant | 22K | $0.00 | $0 | 22K |
| 2026-05-03 | Lin Shao-Lee | CHIEF EXECUTIVE OFFICER | Grant | 328K | $0.00 | $0 | 328K |
| 2025-12-30 | Sarraf Pasha | Director | Buy | 77K | $0.30 | $23K | 324K |
| 2025-12-30 | Sarraf Pasha | Director | Buy | 78K | $0.31 | $24K | 246K |
| 2025-12-30 | Sarraf Pasha | Director | Buy | 87K | $0.32 | $28K | 168K |
| 2025-12-30 | Sarraf Pasha | Director | Buy | 77K | $0.30 | $23K | 81K |
| 2025-12-30 | Sarraf Pasha | Director | Buy | 4K | $0.31 | $1K | 4K |
| 2024-12-16 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Buy | 30K | $1.03 | $31K | 165K |
| 2023-08-25 | Suri Anish | PRESIDENT AND CSO | Buy | 4K | $2.76 | $11K | 136K |
| 2023-08-14 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Buy | 3K | $2.86 | $9K | 135K |
| 2023-03-23 | Kiener Peter A | Director | Sell | 9K | $3.28 | $31K | 357 |
| 2023-03-23 | Kiener Peter A | Director | Exercise or conversion | 10K | $2.86 | $28K | 10K |
| 2022-08-22 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Tax withholding | 3K | $3.05 | $9K | 14K |
| 2022-08-21 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Exercise or conversion | 7K | price not stated in the filing | not stated | 17K |
| 2022-06-14 | Gray Cameron | Director | Tax withholding | 52K | $3.20 | $165K | 687K |
| 2022-06-14 | Gray Cameron | Director | Exercise (in or at the money) | 61K | $2.70 | $165K | 739K |
| 2022-05-27 | Morich Frank | Director | Buy | 28K | $3.75 | $105K | 28K |
| 2022-05-24 | Fletcher Aaron G.L. | Director | Buy | 55K | $3.34 | $184K | 940K |
| 2022-05-23 | Fletcher Aaron G.L. | Director | Buy | 150K | $3.52 | $528K | 885K |
| 2022-03-31 | Fletcher Aaron G.L. | Director | Buy | 735K | $4.76 | $3.5M | 735K |
| 2022-03-31 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 75K | price not stated in the filing | not stated | 174K |
| 2022-03-31 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Gift | 10K | $0.00 | $0 | 132K |
| 2022-03-31 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Tax withholding | 32K | $4.88 | $157K | 142K |
| 2022-03-31 | Suri Anish | PRESIDENT AND CSO | Exercise or conversion | 17K | price not stated in the filing | not stated | 111K |
| 2022-03-31 | Suri Anish | PRESIDENT AND CSO | Tax withholding | 7K | $4.88 | $34K | 104K |
| 2021-11-16 | Kiener Peter A | Director | Exercise or conversion | 1K | $2.86 | $4K | 1K |
| 2021-11-16 | Kiener Peter A | Director | Sell | 1K | $18.02 | $25K | 0 |
| 2021-11-15 | Suri Anish | President and CSO | Exercise or conversion | 8K | $8.26 | $66K | 102K |
| 2021-11-15 | Suri Anish | President and CSO | Sell | 8K | $18.05 | $144K | 94K |
| 2021-11-15 | Kiener Peter A | Director | Sell | 19K | $17.92 | $337K | 0 |
| 2021-11-15 | Kiener Peter A | Director | Exercise or conversion | 19K | $2.86 | $54K | 19K |
| 2021-11-11 | Suri Anish | President and CSO | Exercise or conversion | 20K | $6.42 | $128K | 114K |
| 2021-11-11 | Suri Anish | President and CSO | Sell | 20K | $15.07 | $301K | 94K |
| 2021-10-06 | Suri Anish | PRESIDENT AND CSO | Tax withholding | 14K | $12.97 | $183K | 94K |
| 2021-10-03 | Suri Anish | PRESIDENT AND CSO | Exercise or conversion | 33K | price not stated in the filing | not stated | 108K |
| 2021-10-01 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Sell | 1K | $14.21 | $18K | 10K |
| 2021-10-01 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Exercise or conversion | 1K | $7.50 | $9K | 12K |
| 2021-09-30 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 75K | price not stated in the filing | not stated | 130K |
| 2021-09-30 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Tax withholding | 32K | $14.57 | $462K | 99K |
| 2021-09-24 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | Buy | 3K | $14.72 | $50K | 55K |
| 2021-09-23 | Suri Anish | PRESIDENT AND CSO | Sell | 20K | $15.23 | $305K | 75K |
| 2021-09-23 | Suri Anish | PRESIDENT AND CSO | Exercise or conversion | 20K | $6.42 | $128K | 95K |
| 2021-08-23 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Tax withholding | 2K | $0.00 | $0 | 10K |
| 2021-08-23 | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | Exercise or conversion | 7K | $0.00 | $0 | 12K |
| 2021-03-16 | Pienta Kenneth | Chief Medical Officer | Sell | 439 | $15.09 | $7K | 2K |
| 2021-03-16 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 439 | $5.00 | $2K | 2K |
| 2021-03-15 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 13K | $5.00 | $65K | 15K |
| 2021-03-15 | Pienta Kenneth | Chief Medical Officer | Sell | 13K | $15.10 | $196K | 2K |
| 2021-02-17 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 1K | $2.86 | $4K | 3K |
| 2021-02-17 | Pienta Kenneth | Chief Medical Officer | Sell | 4K | $15.06 | $64K | 2K |
| 2021-02-17 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 3K | $5.00 | $15K | 6K |
| 2021-02-16 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 16K | $2.86 | $46K | 18K |
| 2021-02-16 | Pienta Kenneth | Chief Medical Officer | Sell | 16K | $15.15 | $242K | 2K |
| 2021-01-20 | Pienta Kenneth | Chief Medical Officer | Buy | 3K | $15.07 | $41K | 5K |
| 2021-01-20 | Pienta Kenneth | Chief Medical Officer | Sell | 3K | $15.07 | $41K | 2K |
| 2021-01-20 | Pienta Kenneth | Chief Medical Officer | Exercise or conversion | 3K | $2.86 | $8K | 5K |
| 2020-11-24 | Fletcher Aaron G.L. | Director | Buy | 7K | $12.64 | $83K | 165K |
| 2020-10-05 | Suri Anish | President and CSO | Tax withholding | 10K | $16.30 | $160K | 58K |
| 2020-10-03 | Suri Anish | President and CSO | Exercise or conversion | 33K | price not stated in the filing | not stated | 68K |
| 2020-09-30 | Gray Cameron | Director | Buy | 5K | $15.30 | $77K | 678K |
| 2020-09-29 | Gray Cameron | Director | Buy | 5K | $15.00 | $75K | 673K |
| 2020-08-24 | Millar Kerri-Ann | CFO | Tax withholding | 2K | $0.00 | $0 | 6K |
| 2020-08-21 | Millar Kerri-Ann | CFO | Exercise or conversion | 7K | $0.00 | $0 | 8K |
| 2020-08-05 | Suri Anish | President and CSO | Exercise or conversion | 800 | $6.42 | $5K | 35K |
| 2020-08-05 | Suri Anish | President and CSO | Sell | 800 | $20.01 | $16K | 35K |
| 2020-08-05 | Sandercock Colin | SVP, General Counsel and Sec | Sell | 13K | $20.00 | $265K | 17K |
| 2020-08-05 | Sandercock Colin | SVP, General Counsel and Sec | Exercise or conversion | 13K | $7.50 | $100K | 30K |
| 2020-08-05 | Sandercock Colin | SVP, General Counsel and Sec | Exercise or conversion | 13K | $7.50 | $100K | 30K |
| 2020-08-05 | Sandercock Colin | SVP, General Counsel and Sec | Sell | 13K | $20.00 | $267K | 17K |
| 2020-08-04 | Suri Anish | President and CSO | Exercise or conversion | 400 | $6.42 | $3K | 35K |
| 2020-08-04 | Suri Anish | President and CSO | Sell | 400 | $20.14 | $8K | 35K |
| 2020-08-04 | Sandercock Colin | SVP, General Counsel and Sec | Sell | 201 | $20.05 | $4K | 17K |
| 2020-08-04 | Sandercock Colin | SVP, General Counsel and Sec | Exercise or conversion | 201 | $7.50 | $2K | 17K |
| 2020-08-03 | Suri Anish | President and CSO | Sell | 6K | $20.01 | $116K | 35K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for CUE worth $1.7M at the prices reported; 4 in the last 90 days worth $1.7M. Latest: Sumita Ray filed on 2026-10-13 to sell 1,844 shares ($52K) from 2026-10-12.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-13 | Sumita RayOfficer, CORPORATE SECRETARY | 2K | $52K | 0.024% | 2026-10-12 | Maxim Group LLC |
| 2026-10-13 | Shao-Lee LinOfficer, Director | 11K | $305K | 0.142% | 2026-10-12 | Maxim Group LLC |
| 2026-08-14 | Shao-Lee LinOfficer, Director | 40K | $1.1M | 0.551% | 2026-08-12 | Maxim Group LLC |
| 2026-08-13 | Sumita RayOfficer, CORPORATE SECRETARY | 9K | $266K | 0.122% | 2026-08-13 | Maxim Group LLC |
| 2025-12-29 | MATTEO GIACOMO LEVISETTIOfficer | 7K | $2K | 0.009% | 2025-12-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of CUE in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Mark E. Strome at 8.5% of the class (644,916 shares), filed 2026-10-08 for an event on 2026-07-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-08 | 13G/Ano. 3 | Mark E. Stromeindividual | 645K | 8.5% | 2026-07-14 |
| 2026-10-08 | 13G/Ano. 3 | Strome Investment Management, LPinvestment adviser, partnership | 643K | 8.5% | 2026-07-14 |
| 2026-10-08 | 13G/Ano. 3 | Strome Group, Inc.corporation | 643K | 8.5% | 2026-07-14 |
| 2026-10-08 | 13G/Ano. 3 | Strome Mezzanine Fund II, LPpartnership | 593K | 7.8% | 2026-07-14 |
| 2026-10-08 | 13G/Ano. 3 | Strome Dynasty, LLCother entity | 50K | 0.7% | 2026-07-14 |
| 2026-10-08 | 13G/Ano. 3 | Strome Mezzanine Fund, LPpartnership | 0 | 0.0% | 2026-07-14 |
| 2026-08-21 | 13D | Shao-Lee Linindividual | 467K | 6.2% | 2026-05-03 |
| 2026-08-14 | 13G | DRIEHAUS CAPITAL MANAGEMENT LLCinvestment company | 292K | 7.0% | 2026-06-30 |
13F holders
Tracked managers holding CUE at their latest 13F. JSON2 of the 30 tracked managers held CUE at their latest 13F, $1.3M in total at quarter-end prices. Citadel Advisors is the largest at $809K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 26K | $809K | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 15K | $464K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Cue Biopharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cue Biopharma (CUE), SEC CIK 1645460, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1645460Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CUE is sold short?
792,553 shares were held short at the 2026-10-15 settlement, 3.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CUE's daily short volume?
On 2026-11-02, 40,334 of the 64,052 CUE shares reported to FINRA were sold short, 63.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CUE have fails to deliver?
The SEC's latest file shows 10,410 CUE shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are CUE insiders buying or selling?
Insiders at CUE reported 15 open-market sells worth $2.4M in the last 90 days and no open-market buys. Latest filing: Lin Shao-Lee (Chief Executive Officer) on 2026-10-12.
Have CUE insiders filed to sell?
5 Form 144 notices on file for CUE worth $1.7M at the prices reported; 4 in the last 90 days worth $1.7M. Latest: Sumita Ray filed on 2026-10-13 to sell 1,844 shares ($52K) from 2026-10-12.
Who owns 5% or more of CUE?
6 holders report 5% or more of CUE in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Mark E. Strome at 8.5% of the class (644,916 shares), filed 2026-10-08 for an event on 2026-07-14.
Which tracked 13F managers own CUE?
2 of the 30 tracked 13F managers held CUE shares at their latest filing, $1.3M in all. The largest: Ken Griffin's Citadel Advisors (26K shares, $809K), Renaissance Technologies (15K shares, $464K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.